SCHEMBL96066

SCHEMBL96066

CC([C]=O)c1ccc(F)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.43
CES1 P23141 3/20 0.43
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
RECQL P46063 1/20 0.36
PSEN1 P49768 2/20 0.36
PSEN2 P49810 2/20 0.36
APH1B Q8WW43 2/20 0.36
NCSTN Q92542 2/20 0.36
APH1A Q96BI3 2/20 0.36
PSENEN Q9NZ42 2/20 0.36
ALDH1A1 P00352 2/20 0.35
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PDE2A O00408 2/20 0.34
MC4R P32245 1/20 0.34
HSD11B1 P28845 1/20 0.34
SLC6A2 P23975 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6141199 0.77 CES2 (0.41) CES2CES1IDO1TDO2RECQL
SCHEMBL18242589 0.77 CES2 (0.47) CES2CES1IDO1TDO2RECQL
SCHEMBL84105 0.76 CES2 (0.46) CES2CES1IDO1TDO2RECQL
SCHEMBL6141021 0.75 CYP3A4 (0.40) CES2CES1IDO1TDO2ALDH1A1
Ammonia Solution, Strong SCHEMBL7989997 0.74 CES2 (0.44) CES2CES1IDO1TDO2RECQL
SCHEMBL18243712 0.73 CES2 (0.44) CES2CES1IDO1TDO2RECQL
SCHEMBL14774740 0.72 CES2 (0.43) CES2CES1IDO1TDO2RECQL
SCHEMBL17897217 0.72 CES2 (0.43) CES2CES1IDO1TDO2RECQL
SCHEMBL17897218 0.72 CES2 (0.43) CES2CES1IDO1TDO2RECQL
SCHEMBL7337984 0.72 CES2 (0.43) CES2CES1IDO1TDO2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed
EP-1517881-A1 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES Syngenta Participations AG (CH) 2005-03-30 EP disclosed
WO-2004002943-A1 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB CES2 4459/4885CES1 2322/4885IDO1 2039/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 CES2 4704/4885CES1 2850/4885IDO1 2948/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 CES2 4704/4885CES1 2850/4885IDO1 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.